- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04130087
Selegiline and Reward Processing
The Effects of a Single Dose on Reward and Emotional Processing in Healthy Volunteers
There has been growing interest in the relationship between reward processing and clinical symptoms of depression such as anhedonia (loss of interest and response to pleasurable activities).
The aim of the study is to investigate the acute effects of a single dose of selegiline (an irreversible monoamine oxidase B inhibitor) on reward and emotional processing in healthy volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There has been growing interest in the relationship between reward processing and clinical symptoms of depression such as anhedonia (loss of interest and response to pleasurable activities). Studies in animals have suggested that the neurotransmitter, dopamine, plays a key role in reward processing. This has given rise to the suggestion that in depression, decrements in dopamine activity lead to impaired reward processing which cause symptoms such as anhedonia and low motivation.
Research in humans into dopamine and reward is limited by suitable pharmacological means to manipulate dopamine activity safely and effectively.
To our knowledge, no previous research has studied the effects of acute administration of the licensed drug, selegiline, on reward and emotional processing. However, a single dose of selegiline effectively inhibits monoamine oxidase B (MAO-B), which should lead to increased dopamine availability in the CNS. Therefore, selegiline may be a useful tool to explore the effect of modifying dopamine availability on reward processing. Acquiring such knowledge through this study could assist in the clinical use of MAO-B inhibition as a target to ameliorate symptoms such as anhedonia as well as increasing our general understanding of reward processing in healthy individuals.
The aim of this study is to explore the effects of acute administration of a standard (10mg) dose of selegiline on reward and emotional processing versus a placebo, in healthy volunteers. At this dose selegiline only has an -MAO-B function therefore the specific impact of MAO-B blockade on reward and emotional processing can be explored.
Research Question: What effect will the administration of a single dose of selegiline have on reward and emotional processing in healthy volunteers?
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mayowa Oyesanya, MD
- Phone Number: 01865 613 176
- Email: mayowa.oyesanya@conted.ox.ac.uk
Study Contact Backup
- Name: Wendy Howard, PhD
- Phone Number: 01865 618 286
- Email: wendy.howard@psych.ox.ac.uk
Study Locations
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX3 7JZ
- Recruiting
- University of Oxford
-
Contact:
- Wendy Howard, PhD
- Phone Number: 01865618286
- Email: wendy.howard@psych.ox.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-40 years of age
- Able to give informed consent for study participation
- Sufficient fluency in English to understand and complete the neuropsychological tasks
Exclusion Criteria:
- Current usage of other regular medication (including the contraceptive pill, the Depo-Provera injection or the progesterone implant, and hormone replacement therapy)
- Any past or current Axis 1 DSM-IV psychiatric disorder
- Significant medical condition
- Pulse < 60 beats per minute at baseline screening
- Current or past gastro-intestinal disorder or irritable bowel syndrome
- Current pregnancy or breastfeeding
- Known lactate deficiency or any other problem absorbing lactose, galactose or glucose
- Current or past history of drug or alcohol dependency
- Participation in a psychological or medical study involving the use of medication within the last 3 months
- Previous participation in a study using the same, or similar, emotional processing tasks
- Smoker > 5 cigarettes per day
- Typically drinks > 6 caffeinated drinks per day
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Selegiline Group
27 healthy participants who will be administered a single 10mg tablet of selegiline hydrochloride.
|
Single 10mg tablet of Selegiline Hydrochloride
|
Placebo Comparator: Placebo Group
27 healthy participants who will be administered a single lactose tablet (placebo)
|
Single Placebo Tablet, identical appearance to experimental tablet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total monetary amount won in reward learning task.
Time Frame: Tested one hour after selegiline/placebo ingestion
|
During this task participants have to repeatedly choose between 2 options.
On each trial one of the options, if chosen by the participant, will result in the participant winning money.
The participant simply has to learn which is the best option to choose so as to win as much money as possible.
|
Tested one hour after selegiline/placebo ingestion
|
Reaction times (milliseconds) in reward learning task
Time Frame: Tested one hour after selegiline/placebo ingestion
|
During this task participants have to repeatedly choose between 2 options.
On each trial one of the options, if chosen by the participant, will result in the participant winning money.
The participant simply has to learn which is the best option to choose so as to win as much money as possible.
|
Tested one hour after selegiline/placebo ingestion
|
Reward sensitivity in reward learning task
Time Frame: Tested one hour after selegiline/placebo ingestion
|
During this task participants have to repeatedly choose between 2 options.
On each trial one of the options, if chosen by the participant, will result in the participant winning money.
The participant simply has to learn which is the best option to choose so as to win as much money as possible.
|
Tested one hour after selegiline/placebo ingestion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reaction Time (milliseconds) on the Faces Dot Probe Task (FDOT)
Time Frame: Tested one hour after selegiline/placebo ingestion
|
The FDOT assesses attention to positive versus negative stimuli using a reaction time measure.
Two faces are presented vertically on the computer screen and replaced by a pair of dots, to which the participant has to respond by indicating whether the dots are vertically or horizontally aligned.
On some trials, one of the two faces presented has an emotional expression (fearful or happy).
On half of the trials, the faces are presented very briefly and immediately replaced by a jumbled face mask.
The reaction time to respond to the dots can be used as a measure of attention to the emotional faces.
|
Tested one hour after selegiline/placebo ingestion
|
Reaction time (milliseconds) in an Emotional Categorisation Task (ECAT)
Time Frame: Tested one hour after selegiline/placebo ingestion
|
The ECAT assesses speed to respond to positive and negative self-referent personality descriptors.
Sixty personality characteristics (30 per valence) selected to be disagreeable (eg, sneering, untidy, hostile) or agreeable (eg, cheerful, honest, optimistic) are presented.
The participants are asked whether they would like or dislike to be referred to as each characteristic.
|
Tested one hour after selegiline/placebo ingestion
|
Performance (number of words recalled) in an emotional recall task (EREC)
Time Frame: Tested one hour after selegiline/placebo ingestion
|
The EREC is a surprise free recall task to assess the incidental encoding of emotional stimuli.
Participants are asked to recall as many of the words previously presented in the ECAT task (See Outcome Measure 4) as they can.
The relative recall of positive versus negative words gives a measure of emotional biases in memory.
This task is not computerised - participants write the recalled words on paper.
|
Tested one hour after selegiline/placebo ingestion
|
Percentage Accuracy(%) on facial expression recognition task (FERT)
Time Frame: Tested one hour after selegiline/placebo ingestion
|
The FERT assesses the interpretation of facial expressions.
Faces with seven different basic emotions (happiness, fear, anger, disgust, sadness, surprise, neutral) are displayed on the screen and participants are required to indicate the expression on the face via a button-press.
Different intensity levels of each emotion are presented, which increases the ambiguity of the facial expression and the sensitivity of the task.
|
Tested one hour after selegiline/placebo ingestion
|
Reaction times (milliseconds) on facial expression recognition task (FERT)
Time Frame: Tested one hour after selegiline/placebo ingestion
|
The FERT assesses the interpretation of facial expressions.
Faces with seven different basic emotions (happiness, fear, anger, disgust, sadness, surprise, neutral) are displayed on the screen and participants are required to indicate the expression on the face via a button-press.
Different intensity levels of each emotion are presented, which increases the ambiguity of the facial expression and the sensitivity of the task.
|
Tested one hour after selegiline/placebo ingestion
|
Percentage accuracy (%) in an Emotional Recognition Memory Task (EMEM)
Time Frame: Tested one hour after selegiline/placebo ingestion
|
The EMEM measures recognition memory for affective words.
Participants are presented with a series of words comprising the pleasant and unpleasant personality words that were previously presented to them in the ECAT, and a set of previously unseen distracter words.
For each word, participants are required to report whether they have previously seen the word.
|
Tested one hour after selegiline/placebo ingestion
|
Reaction times (milliseconds) in Emotional Recognition Memory Task (EMEM)
Time Frame: Tested one hour after selegiline/placebo ingestion
|
The EMEM measures recognition memory for affective words.
Participants are presented with a series of words comprising the pleasant and unpleasant personality words that were previously presented to them in the ECAT, and a set of previously unseen distracter words.
For each word, participants are required to report whether they have previously seen the word.
|
Tested one hour after selegiline/placebo ingestion
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Machado-Vieira R, Salvadore G, Diazgranados N, Zarate CA Jr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther. 2009 Aug;123(2):143-50. doi: 10.1016/j.pharmthera.2009.02.010. Epub 2009 May 3.
- Vrieze E, Pizzagalli DA, Demyttenaere K, Hompes T, Sienaert P, de Boer P, Schmidt M, Claes S. Reduced reward learning predicts outcome in major depressive disorder. Biol Psychiatry. 2013 Apr 1;73(7):639-45. doi: 10.1016/j.biopsych.2012.10.014. Epub 2012 Dec 8.
- Admon R, Pizzagalli DA. Dysfunctional Reward Processing in Depression. Curr Opin Psychol. 2015 Aug 1;4:114-118. doi: 10.1016/j.copsyc.2014.12.011.
- Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013 Jun 15;73(12):1133-41. doi: 10.1016/j.biopsych.2013.03.026.
- Heinonen EH, Anttila MI, Nyman LM, Pyykko KA, Vuorinen JA, Lammintausta RA. Inhibition of platelet monoamine oxidase type B by selegiline. J Clin Pharmacol. 1997 Jul;37(7):597-601. doi: 10.1002/j.1552-4604.1997.tb04341.x.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- R64689/RE001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on Selegiline Hydrochloride 10 MG
-
National Institute on Drug Abuse (NIDA)CompletedMarijuana AbuseUnited States
-
Azienda Ospedaliera Universitaria Integrata VeronaUniversity of MilanUnknown
-
International Bio serviceNot yet recruiting
-
National Institute of Allergy and Infectious Diseases...National Institute of Neurological Disorders and Stroke (NINDS); Neurologic...CompletedHIV Infections | Cognition DisordersUnited States
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Cognitive DisordersUnited States
-
Merck Sharp & Dohme LLCCompleted
-
PfizerCompleted
-
Idorsia Pharmaceuticals Ltd.Completed
-
Ludwig-Maximilians - University of MunichCompletedMénière's DiseaseGermany